SCHEMBL2833474

SCHEMBL2833474

C#CCCOC(=O)c1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.59
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 1/20 0.47
ADRB2 P07550 3/20 0.47
ADRB1 P08588 3/20 0.47
ADRB3 P13945 3/20 0.47
TSHR P16473 4/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TP53 P04637 2/20 0.45
HTT P42858 1/20 0.45
MAPK1 P28482 2/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837860 0.90 NPC1 (0.56) NPC1ALDH1A1ADRB2ADRB1ADRB3
SCHEMBL11544365 0.90 NPC1 (0.67) NPC1MEN1KMT2AALDH1A1TSHR
SCHEMBL2831442 0.89 NPC1 (0.54) NPC1ALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2834927 0.84 NPC1 (0.82) NPC1KMT2AALDH1A1ADRB2ADRB1
SCHEMBL2834373 0.83 KMT2A (0.50) NPC1MEN1KMT2AALDH1A1CES2
SCHEMBL9178035 0.83 ALDH1A1 (0.47) NPC1MEN1KMT2AALDH1A1ADRB2
SCHEMBL4672375 0.82 NPC1 (0.53) NPC1MEN1KMT2AALDH1A1ADRB2
SCHEMBL2833985 0.81 RAB9A (0.50) NPC1MEN1KMT2AALDH1A1CES2
SCHEMBL11317858 0.80 HRH3 (0.52) NPC1MEN1KMT2AALDH1A1ADRB2
SCHEMBL14389377 0.79 ALDH1A1 (0.76) ALDH1A1ADRB2ADRB1ADRB3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 NPC1 962/4885MEN1 2371/4885KMT2A 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.